Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/19/3010 |
| _version_ | 1827654766849687552 |
|---|---|
| author | Béatrice Clémenceau Amandine Le Bourgeois Thierry Guillaume Marianne Coste-Burel Pierre Peterlin Alice Garnier Maxime Jullien Jocelyn Ollier Audrey Grain Marie C. Béné Patrice Chevallier |
| author_facet | Béatrice Clémenceau Amandine Le Bourgeois Thierry Guillaume Marianne Coste-Burel Pierre Peterlin Alice Garnier Maxime Jullien Jocelyn Ollier Audrey Grain Marie C. Béné Patrice Chevallier |
| author_sort | Béatrice Clémenceau |
| collection | DOAJ |
| description | A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 <i>n</i> = 40) or two (V4 <i>n</i> = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (<1 year <i>n</i> = 9). Results were compared with those of 12 controls who had received only one booster (BNT162b2 <i>n</i> = 6; mRNA-1273 <i>n</i> = 6). All controls developed protective antibody levels (>250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, <i>p</i> = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients. |
| first_indexed | 2024-03-09T21:53:29Z |
| format | Article |
| id | doaj.art-12afd470f4724f4ba73f3c704550e101 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T21:53:29Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-12afd470f4724f4ba73f3c704550e1012023-11-23T20:01:04ZengMDPI AGCells2073-44092022-09-011119301010.3390/cells11193010Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell RecipientsBéatrice Clémenceau0Amandine Le Bourgeois1Thierry Guillaume2Marianne Coste-Burel3Pierre Peterlin4Alice Garnier5Maxime Jullien6Jocelyn Ollier7Audrey Grain8Marie C. Béné9Patrice Chevallier10Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, F-44000 Nantes, FranceHematology Department, Nantes University Hospital, F-44000 Nantes, FranceNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, F-44000 Nantes, FranceVirology Department, Nantes University Hospital, F-44000 Nantes, FranceHematology Department, Nantes University Hospital, F-44000 Nantes, FranceHematology Department, Nantes University Hospital, F-44000 Nantes, FranceHematology Department, Nantes University Hospital, F-44000 Nantes, FranceNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, F-44000 Nantes, FranceNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, F-44000 Nantes, FranceNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, F-44000 Nantes, FranceNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, F-44000 Nantes, FranceA full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 <i>n</i> = 40) or two (V4 <i>n</i> = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (<1 year <i>n</i> = 9). Results were compared with those of 12 controls who had received only one booster (BNT162b2 <i>n</i> = 6; mRNA-1273 <i>n</i> = 6). All controls developed protective antibody levels (>250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, <i>p</i> = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients.https://www.mdpi.com/2073-4409/11/19/3010allogeneic hematopoietic stem cell transplantationCOVID-19anti-SARS-CoV-2 vaccinesboosterhumoral immunitycellular immunity |
| spellingShingle | Béatrice Clémenceau Amandine Le Bourgeois Thierry Guillaume Marianne Coste-Burel Pierre Peterlin Alice Garnier Maxime Jullien Jocelyn Ollier Audrey Grain Marie C. Béné Patrice Chevallier Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients Cells allogeneic hematopoietic stem cell transplantation COVID-19 anti-SARS-CoV-2 vaccines booster humoral immunity cellular immunity |
| title | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
| title_full | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
| title_fullStr | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
| title_full_unstemmed | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
| title_short | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
| title_sort | strong sars cov 2 t cell responses after one or two covid 19 vaccine boosters in allogeneic hematopoietic stem cell recipients |
| topic | allogeneic hematopoietic stem cell transplantation COVID-19 anti-SARS-CoV-2 vaccines booster humoral immunity cellular immunity |
| url | https://www.mdpi.com/2073-4409/11/19/3010 |
| work_keys_str_mv | AT beatriceclemenceau strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT amandinelebourgeois strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT thierryguillaume strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT mariannecosteburel strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT pierrepeterlin strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT alicegarnier strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT maximejullien strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT jocelynollier strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT audreygrain strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT mariecbene strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT patricechevallier strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients |